Global pharmaceutical sales will reach $1.3 trillion in 2018
Release time：2015-08-26
Author：
Thomson Reuters annual CMRFactbook pointed out that 46 new molecular entities were approved for listing in developed countries in 2014, which is far higher than the number in any year since 2005. At the same time, 2014 was also a year of outstanding sales, with $1 trillion. The sales of the United States challenged those who had a negative attitude towards the pharmaceutical industry.
The report pointed out that the therapeutic field to which the new drugs belong is also encouraging. Among them, 1/3 of the drugs are drugs for the treatment of rare diseases, and 2/3 of the drugs are Junior College drugs for the treatment of cancer, hepatitis C and other diseases. The market price of many drugs is also surprising. Mercadon's Keytruda and Bristome Squibb's Opdivo, and of course the hepatitis C drug leader Hua Dan Sovaldi and Harvoni from Gilead Science, play a very important role in driving the increase in drug spending.
The diversified late-stage R & D pipeline shows that the R & D-focused pharmaceutical industry is constantly focusing on drugs that can stand on the market at high prices. Thomson Reuters pointed out that among all therapeutic areas, the field of anti-tumor drugs continues to attract the highest amount of investment and financing, and most of the newly launched anti-cancer drugs have been granted orphan drug status by the regulatory authorities.
With the advent of high-priced drugs, the question of how the health insurance system pays for these expensive new drugs has arisen, and some payers are now pushing prescription restrictions and performance-based pay models to reduce drug costs. In addition to drug cost affordability, a clear phenomenon is that the pharmaceutical industry has finally improved its drug development efficiency.
Throughout the industry, the volume of pipelines in the early R & D stage decreases, while the volume of pipelines in the later R & D stage increases. At the same time, the number of drugs in Phase III is decreasing, which means that the ability of pharmaceutical companies to identify non-viable drugs in the early stages of development is becoming stronger.
All this opens up a healthy situation for the pharmaceutical industry: sales in 2018 are expected to reach $1.3 trillion, up 25% from $1.04 trillion last year.
Related News
2024/01/18
Mobile Web